艾昂尼斯制药

最新新闻

• 评级变动
  H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Goldman Sachs Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $56
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $70 to $100
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $95
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• 评级变动
  BMO Capital Downgrades Ionis Pharmaceuticals(IONS.US) to Hold Rating, Cuts Target Price to $61
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• 评级变动
  A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $84 to $104
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $85
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $61 to $115
  \u5e02\u573a\u8d44\u8baf · 2026/9/5
• 评级变动
  Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $90
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 公司公告
  Liberta: Announcement that Family Service Eiko Co., Ltd. will hold a press conference for the first time in Tokyo to remove heavy metal ions, PFOS, and PFOA removal water server “swee,” which was jointly developed by Family Service Eiko Co., Ltd. with Shinshu University
  JPX · 2025/4/11
• 评级变动
  Guggenheim Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $80
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• BMO Capital Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $54
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $84 to $100
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Ionis Pharmaceuticals (IONS)
  TipRanks · 2026/9/23
• 评级变动
  J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $104
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 公司公告
  Cacco: Ion's online market, "Green Beans", has adopted "O-PLUX" as a measure against credit card fraud.
  JPX · 2024/6/6
• 评级变动
  Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  H.C. Wainwright Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/9/4

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。